Biomarkers in Clinical Trials in Mexico

Clinical Trials in: Mexico, Argentina, Colombia and Brazil.

Locally-Based, Full Service CRO

Contact us today to learn more.

+ 0
Sites Throughout LATAM
+ 200
Patients in our network
+ 0
Conducted Studies
0 %
Lost-to-Follow Up rate
As a leading CRO in LATAM, we specialize in supporting clinical trials throughout the region. Our extensive experience and broad network of clinical sites enable us to execute trials with speed and efficiency, ensuring high patient recruitment and retention rates.

Biomarkers in Clinical Trials in Mexico

Biomarkers in Clinical Trials in Mexico – Clinical Research Studies

In recent years, the field of clinical trials in Mexico has witnessed a significant transformation with the integration of biomarkers. These remarkable tools have revolutionized the way researchers approach the development of new treatments and therapies.

Biomarkers provide valuable insights into the complex mechanisms of diseases, allowing for personalized medicine approaches and more accurate assessments of treatment efficacy. This blog post will explore the role of biomarkers in clinical trials conducted in Mexico, highlighting their impact on healthcare advancements and patient outcomes.

Understanding Biomarkers

Before delving into their significance in clinical trials, it is essential to understand what biomarkers are. Biomarkers are measurable indicators that reflect normal biological processes, pathogenic processes, or the response to a therapeutic intervention.

These markers can be found in various bodily fluids, tissues, or even genetic material. In clinical trials, biomarkers serve as objective and quantifiable measures to assess the progression of diseases, predict treatment response, and monitor the safety and efficacy of novel interventions.

Advantages of Biomarkers in Clinical Trials

The integration of biomarkers in clinical trials in Mexico offers numerous advantages. Firstly, biomarkers allow for the identification of specific patient populations that are more likely to respond to a particular treatment, enabling researchers to design more targeted trials.

By tailoring treatments to individuals based on their biomarker profiles, the chances of successful outcomes are significantly enhanced, while minimizing the risks of adverse effects.

Moreover, biomarkers can expedite the drug development process. By using biomarkers as surrogate endpoints, researchers can measure treatment response earlier in the clinical trial, reducing the duration and cost of the trials. This acceleration can potentially hasten the availability of life-saving therapies to patients in Mexico.

Biomarkers in Clinical Trials in Mexico

Biomarkers in Clinical Trials in Mexico

Biomarkers in Clinical Trials in Mexico

Role of Biomarkers in Precision Medicine

Precision medicine, an emerging approach in healthcare, relies heavily on biomarkers. In Mexico, biomarkers are playing a crucial role in advancing personalized treatment strategies. By analyzing an individual’s unique genetic makeup and biomarker expression patterns, researchers can predict disease susceptibility, prognosis, and response to specific treatments.

Biomarkers also enable clinicians to monitor treatment response in real-time, adjusting therapies accordingly. This dynamic approach to patient care allows for individualized dosing and treatment schedules, optimizing outcomes while reducing unnecessary interventions.

In Mexico, the use of biomarkers in precision medicine is particularly significant in oncology. Biomarker testing, such as HER2 status in breast cancer or EGFR mutation analysis in lung cancer, helps guide treatment decisions, ensuring patients receive the most appropriate therapies.

This targeted approach not only improves patient outcomes but also reduces the burden on the healthcare system by avoiding ineffective or potentially harmful treatments.

Regulatory Considerations and Challenges

While the integration of biomarkers in clinical trials has shown great promise, it is not without challenges. Regulatory agencies in Mexico, such as COFEPRIS, play a vital role in ensuring the safety and efficacy of biomarker-driven therapies. Proper validation and standardization of biomarker assays are essential to maintain the reliability and reproducibility of results.

Additionally, access to cutting-edge biomarker technologies and expertise can be limited, particularly for smaller research institutions and under-resourced healthcare settings. Collaborations between academic institutions, private industry, and regulatory bodies are necessary to address these challenges and ensure equitable access to biomarker-driven clinical trials throughout Mexico.


Biomarkers have emerged as powerful tools in clinical trials, transforming the landscape of healthcare in Mexico. Their integration enables precision medicine approaches, leading to improved patient outcomes and more efficient drug development processes.

The use of biomarkers in clinical trials has the potential to revolutionize the way diseases are diagnosed, monitored, and treated in Mexico. With continued advancements in biomarker technologies and increased collaboration among stakeholders, Mexico is poised to make significant strides in personalized medicine and the development of innovative therapies.

Biomarkers in Clinical Trials in Mexico

Source: Roche

Biomarkers in Clinical Trials in Mexico

Welcome to Cohortias!

of Latin America

Simplify Your Clinical Trials with Our Expert Infrastructure in Latin America

Say goodbye to the complex, costly, and disorganized process of conducting clinical trials. Our infrastructure in Latin America streamlines the launch of studies and ensures adherence to international standards. Schedule a call with us today to discover the path to simplified clinical research in Latin America.

Biomarkers in Clinical Trials in Mexico

Explore What We Are Doing Better

We define ourselves as a unique team, capable of blending our academic background with a global business mindset to bring the highest standard of quality and operational excellence into clinical research in Latin America.

Early Phase Trials

- First-in-Human Studies.
- Get to patients faster, no IND necessary.
- Valid data for FDA submission.

Rescue Studies

- Regain lost time and boost patient recruitment.
- We work alongside Global CROs to get studies back on track.
- More than 200 sites available.

Phase II & III Trials

- Full-Service Clinical Outsourcing.
- Proven infrastructure that can handle any trial.
- Local Regulatory Experts
- Wide network of sites and physicians.

Medical Devices

- A fast-track platform that will meet your timeline.
- We take care of everything, from shipping requirements all the way to data collection.
Biomarkers in Clinical Trials in Mexico

Full Service CRO in LATAM

Outsourcing Clinical Trials to Latin America

Unlock the advantages and opportunities of outsourcing clinical trials to Latin America. Diverse patient population, streamlined regulations, and cost-effectiveness

Lower Operating Costs

From lower labor costs to lower costs for rent, utilities, and equipment, you can save money on your clinical trial budget while still ensuring the quality of your trial

Access to Emerging Markets

Latin America offers access to emerging markets, providing an opportunity for pharmaceutical companies to expand their reach and reach new patient populations.

Biomarkers in Clinical Trials in Mexico

Cohortias is redefining Clinical Research in Latin America

We are committed to become leaders in providing clinical research services in Latin America. Here at Cohortias, we combine our academic roots, proven experience and a large pool of patients from an extensive network of sites.

Our main purpose is to deliver high quality data.

Biomarkers in Clinical Trials in Mexico

Clinical Research in Latin America

Cohortias has built an extensive and highly reputable network of clinical sites which can access patients in a timely manner and operate within a standard-of-care comparable to the U.S. healthcare system.


  • Site Management

  • Data Management

  • Site Selection

  • Regulatory Submissions

  • Clinical Monitoring

  • Protocol Development


Beta Trials Platform

  • First-in-human studies

Medical Devices

  • Pilot and Pivotal Device Studies

Phases I – III

  • We partner with our clients to bring their products in a fast and efficient manner to the market with the highest quality standards


  • Diabetes/Metabolic Syndromes
  • Infectious Diseases
  • Cardiovascular
  • Neurology
  • Respiratory
  • Oncology

Biomarkers in Clinical Trials in Mexico

Clinical Research in Latin America

Academic Leadership and Extensive Clinical Site Network for Efficient Clinical Trials

  • Our peer-to-peer management approach guarantees high patient recruitment and retention in any clinical trial

High Speed Execution

  • We offer the quickest start-up times in each country.
  • Efficient Clinical Site Selection and Contracting.
  • Benefit from our extensive network of clinical sites and streamlined contracting process.

Operational Excellence

  • Proven record of delivering rescue studies, we consistently exceed industry performance standards.
  • Our team provides efficient query resolution to keep your trial on track.

Business Insight and Flexibility

  • We offer innovative pricing models and short lines of communication to ensure maximum flexibility and cost-effectiveness.
  • At Cohortias, we prioritize  short lines of communication to ensure efficient collaboration.
  • Swift adaptation to changes in the trial landscape to keep your study on schedule.

Biomarkers in Clinical Trials in Mexico

We provide our services with offices in:

Colombia &

Daniela Maresca
Daniela Maresca | Country Lead Argentina
Martín Hernández-Torre | CMO
Maritza Rojas | CRA II
Pedro Alvarez | Business Development Manager
Samantha Rodriguez Cohortias
Samantha Rdz. | Start-Up Manager
Biomarkers in Clinical Trials in Mexico

The Cohortias Team

Biomarkers in Clinical Trials in Mexico

As the largest South American Contract research Organization, we know the Advantages and Challenges Of the Region

Let Us Guide You Through The Latin American Clinical Research Landscape

Biomarkers in Clinical Trials in Mexico

Network & Partnerships